Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Eiger BioPharmaceuticals (EIGR) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial.

The post Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today? appeared first on InvestorPlace.

• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• ChatGPT IPO Could Shock the World, Make This Move Before the Announcement
• It doesn’t matter if you have $500 or $5 million. Do this now.